Astellas Pharma News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

30.10.24	Biotech Stocks Facing FDA Decision In November 2024 (RTTNews)
30.10.24	Astellas Pharma H1 Profit Rises; Lifts FY24 Outlook (RTTNews)
18.10.24	Astellas Pharma's VYLOY Receives FDA Approval For Treatment Of Advanced Gastric And GEJ Cancer (RTTNews)
08.10.24	Astellas Receives Option To License AVB-101 - Quick Facts (RTTNews)
19.09.24	Astellas Announces FDA Listing Of DIGITIVA For Heart Failure Management (RTTNews)
28.08.24	Astellas : EC Approves PADCEV Combination For First-Line Treatment Of Advanced Urothelial Cancer (RTTNews)
20.08.24	Astellas : China Approves Padcev For Treatment Of Locally Advanced Or Metastatic Urothelial Cancer (RTTNews)
28.07.24	Astellas: Zolbetuximab Combo Gets Positive CHMP Opinion In Advanced Gastric &Gastroesophageal Cancer (RTTNews)
22.07.24	Astellas, Osaka University To Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy (RTTNews)
31.05.24	FDA Acknowledges Astellas Pharma's Resubmission Of BLA For Zolbetuximab (RTTNews)
02.05.24	Astellas, Poseida Collaborate To Develop Novel Allogeneic Cell Therapies In Oncology (RTTNews)
24.04.24	European Commission Approves Astellas' Xtandi For Recurrent Early Prostate Cancer Treatment (RTTNews)
22.04.24	Takeda, Astellas, Sumitomo Mitsui Banking To Form JV For Incubation Of Early Drug Discovery Programs (RTTNews)
28.03.24	Astellas & Pfizer's SBLA For Enfortumab Vedotin With Keytruda Gets Approval In China (RTTNews)
22.03.24	Astellas Pharma Gets Positive CHMP Opinion For XTANDI In Early Prostate Cancer Treatment Setting (RTTNews)
31.01.24	Astellas Submits SNDA In Japan For PADCEV-KEYTRUDA For Advanced Bladder Cancer Treatment (RTTNews)
31.01.24	Astellas Pharma Announces Collaboration With Mass General Brigham (RTTNews)
09.01.24	FDA Issues Complete Response Letter For Astellas' Zolbetuximab In HER2-Negative Gastric Cancer (RTTNews)
28.12.23	Biotech Stocks Facing FDA Decision In January 2024 (RTTNews)
28.12.23	Elpiscience Biopharma, Astellas Pharma Collaborate For Novel Bi-specific Macrophage Engagers (RTTNews)
28.12.23	Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager (PR Newswire)
22.12.23	Astellas Completes Acquisition of Propella Therapeutics (PR Newswire)
18.12.23	EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children (PR Newswire)
16.12.23	Pfizer : FDA Approves Padcev-Keytruda To Treat Advanced Bladder Cancer (RTTNews)
15.12.23	PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer (PR Newswire)
13.12.23	Astellas and MBC BioLabs Announce 2023 Future Innovator Prize Awarded to TippingPoint Biosciences and Altay Therapeutics (PR Newswire)
11.12.23	Basilea Pharma: Astellas Pharma Gets FDA Approval For Cresemba's Expanded Use In Kids With IA, IM (RTTNews)
11.12.23	Astellas' Veoza Approved In Europe For Treatment Of Vasomotor Symptoms Associated With Menopause (RTTNews)
11.12.23	Astellas' VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause (PR Newswire)
01.12.23	Astellas : FDA Grants Priority Review For SBLA Of Padcev Combination For Bladder Cancer Treatment (RTTNews)
30.11.23	FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer (PR Newswire)
30.11.23	Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy (PR Newswire)
17.11.23	Pfizer, Astellas' XTANDI Gets FDA Approval For Nonmetastatic Castration-sensitive Prostate Cancer (RTTNews)
17.11.23	Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting (PR Newswire)
16.11.23	University of Tsukuba and Astellas Confirm a Strategic Partnership (PR Newswire)
16.11.23	Astellas Pharma To Buy Propella Therapeutics For About $175 Mln (RTTNews)
16.11.23	Astellas to Acquire Propella Therapeutics (PR Newswire)
16.11.23	Astellas Announces Data from ASPIRO Study in X-linked Myotubular Myopathy Published in The Lancet Neurology (PR Newswire)
05.11.23	Astellas : Izervay Monthly Or Every Other Month Reduced GA Lesion Growth Through 2 Years (RTTNews)
04.11.23	IZERVAY™ (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 Years (PR Newswire)
01.11.23	Astellas Pharma H1 Profit Down; Cuts FY23 Profit View, Lifts Revenue Forecast (RTTNews)
22.10.23	Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-L... (PR Newswire)
16.10.23	Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023 (PR Newswire)
13.10.23	Astellas' Veoza Receives Positive CHMP Opinion For Treatment Of VMS Associated With Menopause (RTTNews)
13.10.23	Astellas Receives Positive CHMP Opinion for VEOZA™ (fezolinetant) (PR Newswire)
11.10.23	Astellas Pharma, BioLabs And Mitsui Fudosan Collaborate To Enhance Life Science Ecosystems In Japan (RTTNews)
11.10.23	Astellas, BioLabs and Mitsui Fudosan Announce a Collaboration to Enhance the Life Science Ecosystems in Tsukuba and Kashiwa-no-ha, Japan (PR Newswire)
22.09.23	Merck Says Phase 3 KEYNOTE-A39/EV-302 Trial Meets Dual Primary Endpoints (RTTNews)
22.09.23	Seagen, Astellas Pharma Report Positive Topline Results From EV-302 Trial (RTTNews)
22.09.23	PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer i... (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Sonova Hldg	311.80	2.57 %	K V
Part Grp Hldg	1’258.50	2.48 %	K V
Novartis	93.42	2.03 %	K V
Geberit	524.80	1.59 %	K V
Roche Hldg G	254.50	1.35 %	K V
Swiss Life Hldg	731.20	0.55 %	K V
UBS Group	28.24	0.36 %	K V
Nestle	76.12	0.21 %	K V
Swisscom	506.50	0.20 %	K V
Kuehne+Nagel Int	207.90	-0.05 %	K V

Nachrichten zu Astellas Pharma Inc Unsponsored American Deposit Receipt Repr 1-4 Sh

Aktien Top/Flop

Meistgelesene Nachrichten